InVivoMAb anti-mouse CD27 BE0348-R001mg from Bio X Cell

Description

Bio X Cell InVivoMAb anti-mouse CD27 Monoclonal Antibody has the following reported applications: in vivo CD27 stimulation, in vitro CD27 stimulation, Immunoprecipitation, Flow cytometry. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMAb anti-mouse CD27
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0348-R001mg
Antibody TypePrimary Antibody
ClonalityMonoclonal
CloneRM27-3E5
IsotypeIgG2a, κ
Quantity1 mg
TargetCD27
HostRat
Purity>95%, Determined by SDS-PAGE
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
Applicationsin vivo CD27 stimulation, in vitro CD27 stimulation, Immunoprecipitation, Flow cytometry
ImmunogenMouse CD27-human IgG1 Fc fusion protein
ReactivityMouse
NCBI Full Gene NameCD27 antigen
NCBI Gene AliasesS152, Tnfrsf7, Tp55
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immune Checkpoint Protein, Immunology

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) CD4⁺ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue InvasivenessImmunityNovember 21, 2017Ahrends T, Spanjaard A, Pilzecker B, Bąbała N, Bovens A, Xiao Y, Jacobs H, Borst J.

(2) Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich TumorCancer researchNovember 1, 2016Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ.

(3) CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer VaccinationCancer researchMay 15, 2016Ahrends T, Bąbała N, Xiao Y, Yagita H, van Eenennaam H, Borst J.

(4) Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cellsJournal of immunotherapy (Hagerstown, Md. : 1997)October 1, 2010Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, Bullock TN.

(5) Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent miceBiochemical and biophysical research communicationsMarch 19, 2010Sakanishi T, Yagita H.

(6) CD27 and CD70 do not play a critical role in the development of experimental allergic conjunctivitis in miceImmunology lettersAugust 15, 2008Sumi T, Ishida W, Ojima A, Kajisako M, Sakanishi T, Yagita H, Fukushima A.

Be the First to Write a Review!